Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment.

MLA

Junji Uchino, et al. “Treatment Rationale and Design of the SPIRAL Study: A Phase II Trial of Osimertinib in Elderly Epidermal Growth Factor Receptor T790M-Positive Nonsmall-Cell Lung Cancer Patients Who Progressed during Prior EGFR-TKI Treatment.” Medicine, vol. 97, no. 23, June 2018, pp. 1–4. EBSCOhost, https://doi.org/10.1097/MD.0000000000011081.

APA

Junji Uchino, Akira Nakao, Nobuyo Tamiya, Yoshiko Kaneko, Tadaaki Yamada, Kenichi Yoshimura, Masaki Fujita, & Koichi Takayama. (2018). Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment. Medicine, 97(23), 1–4. https://doi.org/10.1097/MD.0000000000011081

Chicago

Junji Uchino, Akira Nakao, Nobuyo Tamiya, Yoshiko Kaneko, Tadaaki Yamada, Kenichi Yoshimura, Masaki Fujita, and Koichi Takayama. 2018. “Treatment Rationale and Design of the SPIRAL Study: A Phase II Trial of Osimertinib in Elderly Epidermal Growth Factor Receptor T790M-Positive Nonsmall-Cell Lung Cancer Patients Who Progressed during Prior EGFR-TKI Treatment.” Medicine 97 (23): 1–4. doi:10.1097/MD.0000000000011081.